PT772619E - Oligonucleotidos imunomoduladores - Google Patents

Oligonucleotidos imunomoduladores

Info

Publication number: PT772619E
Authority: PT; Portugal
Prior art keywords: oligonucleotidos; imunomoduladores; stabilised; contain; cpg dinucleotide
Prior art date: 1994-07-15

Application number

PT95911630T

Other languages

English (en)

Inventor

Arthur M Krieg

Klinman Dennis

Alfred D Steinberg

Original Assignee

Univ Iowa Res Found

Us Health

Ry Dept Of Health And Human Se

Coley Pharm Group Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-15

Filing date

1995-02-07

Publication date

2006-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23056334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT772619(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-07 Application filed by Univ Iowa Res Found, Us Health, Ry Dept Of Health And Human Se, Coley Pharm Group Inc filed Critical Univ Iowa Res Found

2006-10-31 Publication of PT772619E publication Critical patent/PT772619E/pt

Links

108091029430 CpG site Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Virology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Neurosurgery (AREA)
Analytical Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Neurology (AREA)
Dermatology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)

PT95911630T 1994-07-15 1995-02-07 Oligonucleotidos imunomoduladores PT772619E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27635894A	1994-07-15	1994-07-15

Publications (1)

Publication Number	Publication Date
PT772619E true PT772619E (pt)	2006-10-31

Family

ID=23056334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT95911630T PT772619E (pt)	1994-07-15	1995-02-07	Oligonucleotidos imunomoduladores

Country Status (12)

Country	Link
US (1)	US6194388B1 (pt)
EP (4)	EP0772619B2 (pt)
JP (7)	JP3468773B2 (pt)
AT (3)	ATE509102T1 (pt)
AU (1)	AU713040B2 (pt)
CA (2)	CA2194761C (pt)
DE (2)	DE69535905D1 (pt)
DK (1)	DK0772619T4 (pt)
ES (3)	ES2267100T5 (pt)
HK (3)	HK1043598A1 (pt)
PT (1)	PT772619E (pt)
WO (1)	WO1996002555A1 (pt)

Families Citing this family (861)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
PT772619E (pt) *	1994-07-15	2006-10-31	Univ Iowa Res Found	Oligonucleotidos imunomoduladores
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
GB2324093A (en)	1996-01-04	1998-10-14	Rican Limited	Helicobacter pylori bacterioferritin
ATE437943T1 (de) *	1996-01-30	2009-08-15	Univ California	Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
FR2750704B1 (fr)	1996-07-04	1998-09-25	Rhone Poulenc Rorer Sa	Procede de production d'adn therapeutique
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
AU768178B2 (en) *	1996-10-11	2003-12-04	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
WO1998016247A1 (en) *	1996-10-11	1998-04-23	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
JP2001513776A (ja) *	1997-02-28	2001-09-04	ユニバーシティオブアイオワリサーチファウンデーション	ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE441432T1 (de) *	1997-03-10	2009-09-15	Ottawa Hospital Res Inst	Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
WO1998051278A2 (en)	1997-05-14	1998-11-19	Inex Pharmaceuticals Corporation	High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US20030104044A1 (en) *	1997-05-14	2003-06-05	Semple Sean C.	Compositions for stimulating cytokine secretion and inducing an immune response
CA2289741A1 (en) *	1997-05-19	1998-11-26	Merck & Co., Inc.	Oligonucleotide adjuvant
EP1003531B1 (en) *	1997-05-20	2007-08-22	Ottawa Health Research Institute	Processes for preparing nucleic acid constructs
CA2291483C (en) *	1997-06-06	2012-09-18	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1374894A3 (en) *	1997-06-06	2004-09-22	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DK1009413T3 (da) *	1997-09-05	2007-06-11	Univ California	Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
GB9724531D0 (en)	1997-11-19	1998-01-21	Smithkline Biolog	Novel compounds
DK1659178T3 (da)	1998-02-05	2010-07-12	Glaxosmithkline Biolog Sa	Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
CA2323929C (en) *	1998-04-03	2004-03-09	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU746163B2 (en) *	1998-04-09	2002-04-18	Smithkline Beecham Biologicals (Sa)	Adjuvant compositions
GB9808866D0 (en)	1998-04-24	1998-06-24	Smithkline Beecham Biolog	Novel compounds
WO1999056755A1 (en) *	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
IL139646A0 (en) *	1998-05-14	2002-02-10	Coley Pharm Group Inc	Methods for regulating hematopoiesis using cpg-oligonucleotides
IL139307A0 (en)	1998-05-19	2001-11-25	Res Dev Foundation	Triterpene compositions and methods for use thereof
BR9910643A (pt) *	1998-05-22	2001-10-30	Loeb Health Res Inst At The Ot	Processos e produtos para a indução de imunidadede mucosa
US6881561B1 (en)	1998-05-27	2005-04-19	Cheil Jedang Corporation	Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
KR19990086271A (ko) *	1998-05-27	1999-12-15	손경식	면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6562798B1 (en) *	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) *	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
AU764532B2 (en) *	1998-07-27	2003-08-21	University Of Iowa Research Foundation, The	Stereoisomers of CpG oligonucleotides and related methods
CN102198266A (zh)	1998-07-31	2011-09-28	株式会社国际癌症免疫研究所	基于癌抑制基因wt1的产物的癌抗原
AU5467899A (en)	1998-08-07	2000-02-28	University Of Washington	Immunological herpes simplex virus antigens and methods for use thereof
ATE315405T1 (de) *	1998-08-10	2006-02-15	Antigenics Inc	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
ES2394458T3 (es) *	1998-09-09	2013-01-31	Genzyme Corporation	Metilación de vectores plasmídicos
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
AU766492B2 (en) *	1998-09-18	2003-10-16	Dynavax Technologies Corporation	Methods of treating IgE-associated disorders and compositions for use therein
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
EP1119375A4 (en) *	1998-10-05	2005-02-02	Regetns Of The University Of C	METHODS AND ADJUVANTS FOR STIMULATING MUCOUS IMMUNITY
KR100629028B1 (ko)	1998-10-16	2006-09-26	글락소스미스클라인 바이오로지칼즈 에스.에이.	애쥬번트 시스템 및 백신
ATE527360T1 (de)	1998-12-08	2011-10-15	Glaxosmithkline Biolog Sa	Neue verbindungen abgeleitet von neisseria meningitidis
HUP0400719A3 (en)	1998-12-08	2010-08-30	Corixa Corp	Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en)	1999-01-29	2007-04-03	Corika Corporation	HER-2/neu fusion proteins
CA2361459A1 (en) *	1999-02-05	2000-08-10	Salam Abdul Kadhim	Use of cationic lipids to generate anti-tumor immunity
CA2362204C (en)	1999-02-17	2011-11-08	John Cooper Cox	Immunogenic complexes and methods relating thereto
WO2000050006A2 (en)	1999-02-26	2000-08-31	Chiron Corporation	Microemulsions with adsorbed macromoelecules and microparticles
ES2228454T3 (es)	1999-02-26	2005-04-16	Chiron S.R.L.	Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
US7666988B1 (en)	1999-03-12	2010-02-23	Glaxosmithkline Biologicals S.A.	BASB082 Polypeptides
CZ303653B6 (cs)	1999-03-19	2013-01-30	Smithkline Beecham Biologicals S. A.	Imunogenní prostredek
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
GB9909077D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Biolog	Novel compositions
JP2000262247A (ja) *	1999-03-19	2000-09-26	Asama Kasei Kk	免疫調節剤、免疫調節食品および免疫調節飼料
EP1169347B1 (en)	1999-04-02	2008-07-02	Corixa Corporation	Compounds and methods for therapy and diagnosis of lung cancer
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (en) *	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynucleotide and its use to induce an immune response
JP2002542203A (ja) *	1999-04-19	2002-12-10	スミスクラインビーチャムバイオロジカルズソシエテアノニム	ワクチン
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
ATE275727T1 (de) *	1999-04-29	2004-09-15	Coley Pharm Gmbh	Screening nach modulatoren der funktion von immunstimulatorischer dna
GB9915204D0 (en) *	1999-06-29	1999-09-01	Smithkline Beecham Biolog	Vaccine
CA2376992A1 (en) *	1999-06-29	2001-01-04	Smithkline Beecham Biologicals S.A.	Use of cpg as an adjuvant for hiv vaccine
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
FR2795963A1 (fr) *	1999-07-08	2001-01-12	Pasteur Merieux Serums Vacc	Polynucleotide immunostimulant
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
US20050244434A1 (en) *	1999-08-12	2005-11-03	Cohen David I	Tat-based tolerogen compositions and methods of making and using same
WO2001012223A2 (en) *	1999-08-19	2001-02-22	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
AU780535B2 (en) *	1999-08-27	2005-03-24	Inex Pharmaceuticals Corp.	Compositions for stimulating cytokine secretion and inducing an immune response
TR200200797T2 (tr) *	1999-09-25	2002-10-21	University Of Iowa Research Foundation	İmmünostimülatör nükleik asitler
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
EP1964573B1 (en)	1999-10-22	2014-11-26	Aventis Pasteur Limited	Method of inducing and/or enhancing an immune response to tumor antigens
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2593701A (en) *	1999-12-21	2001-07-03	Regents Of The University Of California, The	Method for preventing an anaphylactic reaction
ATE378348T1 (de)	2000-01-14	2007-11-15	Us Health	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
CA2398756A1 (en) *	2000-01-31	2001-08-02	Eyal Raz	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805264B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
FR2805265B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
US6613751B2 (en)	2000-02-23	2003-09-02	The Regents Of The University Of California	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
BR0108654A (pt)	2000-02-23	2003-04-29	Smithkline Beecham Biolog	Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
US20030130217A1 (en) *	2000-02-23	2003-07-10	Eyal Raz	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
CA2405424A1 (en) *	2000-04-07	2001-10-18	The Regents Of The University Of California	Synergistic improvements to polynucleotide vaccines
DE60133190T2 (de)	2000-04-21	2009-04-02	CORIXA CORP., Wilmington	Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
AU5810201A (en)	2000-05-10	2001-11-20	Aventis Pasteur	Immunogenic polypeptides encoded by mage minigenes and uses thereof
PT1284740E (pt)	2000-05-19	2008-07-09	Corixa Corp	Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos
WO2001098460A2 (en)	2000-06-20	2001-12-27	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
JP2003535907A (ja)	2000-06-22	2003-12-02	ユニバーシティオブアイオワリサーチファウンデーション	抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
AR029540A1 (es)	2000-06-28	2003-07-02	Corixa Corp	COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
PT1946769E (pt)	2000-06-29	2012-06-27	Smithkline Beecham Biolog	Composição de vacina multivalente com dose reduzida de haemophilus influenzae de tipo b
US7229623B1 (en)	2000-08-03	2007-06-12	Corixa Corporation	Her-2/neu fusion proteins
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
AU2001285421A1 (en) *	2000-08-10	2002-02-18	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Vaccine against rsv
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
IL154557A0 (en) *	2000-08-25	2003-09-17	Yeda Res & Dev	Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide
US6943240B2 (en)	2000-09-15	2005-09-13	Coley Pharmaceuticals Gmbh	Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
KR100831139B1 (ko)	2000-10-18	2008-05-20	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
EP1671981A3 (en)	2000-10-27	2006-07-05	Chiron SRL.	Nucleic acids and proteins from streptococcus group A
AU2001297693A1 (en) *	2000-12-08	2002-09-12	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
AU2006216669A1 (en) *	2000-12-08	2006-08-31	3M Innovative Properties Company	Compositions and methods for targeted delivery of immune response modifiers
ATE471374T1 (de) *	2000-12-27	2010-07-15	Dynavax Tech Corp	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
JPWO2002055091A1 (ja) *	2001-01-12	2004-05-13	天藤製薬株式会社	抗アレルギー剤
KR20030070101A (ko) *	2001-01-12	2003-08-27	아마토 세이야쿠 가부시키가이샤	미생물 감염 방지제
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
EA200300828A1 (ru) *	2001-01-24	2003-12-25	Амато Фармасьютикал Продактс, Лтд.	Средство против стресса
DE10105234A1 (de)	2001-02-02	2002-08-29	Schoeller Textil Ag Sevelen	Textile Fläche
GB0103171D0 (en)	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
GB0105360D0 (en) *	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens
CN1281625C (zh)	2001-03-22	2006-10-25	株式会社癌免疫研究所	经修饰的wt1肽
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
ES2288555T3 (es)	2001-05-21	2008-01-16	Intercell Ag	Moleculas de oligodesoxinucleotidos inmunoestimuladores.
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
US8114418B2 (en)	2001-06-21	2012-02-14	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—IV
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
NZ530632A (en) *	2001-06-29	2007-04-27	Chiron Corp	HCV E1E2 vaccine compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or CpG oligonucleotides
EP2241309A3 (en)	2001-07-10	2012-12-26	Corixa Corporation	Methods for encapsulation of proteins and adjuants in microspheres
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003012061A2 (en) *	2001-08-01	2003-02-13	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
US20030072762A1 (en) *	2001-08-03	2003-04-17	Van De Winkel Jan G. J.	Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies
EP1420829A4 (en)	2001-08-07	2006-05-17	Dynavax Tech Corp	IMMUNOMODULATING COMPOSITIONS, FORMULATIONS AND METHOD FOR THEIR USE
AU2002361468A1 (en) *	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
CA2457485C (en)	2001-08-17	2012-08-14	Arthur M. Krieg	Combination motif immune stimulatory oligonucleotides with improved activity
CN100488981C (zh)	2001-08-24	2009-05-20	维多利亚大学创新和发展公司	含有蛋白酶激活序列的气单胞菌溶素原及其应用
US20030133913A1 (en) *	2001-08-30	2003-07-17	3M Innovative Properties Company	Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
US7709451B2 (en) *	2001-09-07	2010-05-04	Trustees Of Boston University	Method and composition for treating immune complex associated disorders
AU2002347404A1 (en) *	2001-09-14	2003-04-01	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CN1599623B (zh)	2001-09-14	2011-05-11	赛托斯生物技术公司	免疫刺激物向病毒样颗粒内的包装:制备方法与用途
AU2002362368B2 (en)	2001-09-20	2006-09-21	Glaxo Group Limited	HIV-gag codon-optimised DNA vaccines
AU2002353783A1 (en)	2001-09-24	2003-04-07	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
US20050002951A1 (en) *	2001-09-28	2005-01-06	Haruo Sugiyama	Novel method of inducing antigen-specific t cells
US8735357B2 (en)	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
WO2003031573A2 (en) *	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
US20030139364A1 (en) *	2001-10-12	2003-07-24	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
TW200303759A (en) *	2001-11-27	2003-09-16	Schering Corp	Methods for treating cancer
EP1450821A1 (en) *	2001-12-07	2004-09-01	Intercell AG	Immunostimulatory oligodeoxynucleotides
ES2528384T3 (es)	2001-12-12	2015-02-09	The Government Of The United States Of America, As Represented By The Secretary Department Of Healt	Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
CA2476755C (en)	2001-12-17	2014-08-26	Corixa Corporation	Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002357359B2 (en) *	2001-12-21	2009-01-08	Csl Limited	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20040034223A1 (en) *	2002-02-07	2004-02-19	Covalent Partners, Llc.	Amphiphilic molecular modules and constructs based thereon
WO2003067286A2 (en) *	2002-02-07	2003-08-14	Covalent Partners, Llc	Nanofilm and membrane compositions
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
EP2572707A3 (en)	2002-02-20	2013-11-06	Novartis Vaccines and Diagnostics, Inc.	Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en)	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
EP2258712A3 (en) *	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
US20070037769A1 (en) *	2003-03-14	2007-02-15	Multicell Immunotherapeutics, Inc.	Compositions and methods to treat and control tumors by loading antigen presenting cells
WO2003078595A2 (en) *	2002-03-15	2003-09-25	Astral, Inc.	Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
CA2480775C (en)	2002-04-04	2016-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory g,u-containing oligoribonucleotides
US20030224013A1 (en) *	2002-04-19	2003-12-04	Cole Garry T.	Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
AU2003229433B2 (en) *	2002-05-10	2008-04-24	Tekmira Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
US20040009943A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Pathogen vaccines and methods for using the same
US20040013649A1 (en) *	2002-05-10	2004-01-22	Inex Pharmaceuticals Corporation	Cancer vaccines and methods of using the same
KR100456681B1 (ko) *	2002-05-22	2004-11-10	주식회사 대웅	박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) *	2002-06-05	2004-01-15	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
SE0201701D0 (sv) *	2002-06-05	2002-06-05	Gotovax Ab	Treatment of epithelial tumors and infections
NZ537002A (en) *	2002-06-20	2006-06-30	Cytos Biotechnology Ag	VLPs bound to immunostimulatory substances for use as adjuvants mixed with an antigen for enhancing immune response
US7575742B2 (en)	2002-06-28	2009-08-18	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
DE10229872A1 (de)	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
WO2004007743A2 (en) *	2002-07-17	2004-01-22	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
DE60335755D1 (de)	2002-07-18	2011-02-24	Univ Washington	Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
CA2484941A1 (en)	2002-07-24	2004-02-05	Intercell Ag	Antigens encoded by alternative reading frame from pathogenic viruses
AU2003263963A1 (en)	2002-08-01	2004-02-23	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
PL220107B1 (pl)	2002-08-02	2015-08-31	Glaxosmithkline Biolog Sa	Preparat immunogenny, szczepionka oraz zastosowanie tej szczepionki
ATE488246T1 (de)	2002-08-15	2010-12-15	3M Innovative Properties Co	Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
JP2006504687A (ja)	2002-09-13	2006-02-09	インターツェル・アクチェンゲゼルシャフト	Ｃ型肝炎ウイルスペプチドの単離方法
US20040106741A1 (en) *	2002-09-17	2004-06-03	Kriesel Joshua W.	Nanofilm compositions with polymeric components
US8263091B2 (en) *	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003268737A1 (en) *	2002-10-02	2004-04-23	Mochida Pharmaceutical Co., Ltd.	Novel method of constructing monoclonal antibody
US8043622B2 (en)	2002-10-08	2011-10-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
JP5116971B2 (ja)	2002-10-15	2013-01-09	インターセルアーゲー	Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
CA2502268A1 (en)	2002-10-23	2004-05-06	Glaxosmithkline Biologicals S.A.	Methods for vaccinating against malaria
AU2003301526A1 (en) *	2002-10-25	2004-05-13	University Of Connecticut Health Center	Immunotherapy of cancer through controlled cell lysis
ATE544466T1 (de) *	2002-10-29	2012-02-15	Coley Pharm Group Inc	Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
WO2004098491A2 (en) *	2002-11-01	2004-11-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
DE60332477D1 (de)	2002-11-15	2010-06-17	Novartis Vaccines & Diagnostic	Unerwartete oberflächenproteine in neisseria meningitidis
EP2322186A3 (en) *	2002-11-21	2011-07-13	Bayhill Therapeutics, Inc.	Methods and immune modulatory nucleic acid compositions for preventing and treating disease
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
EP1578954A4 (en) *	2002-12-11	2010-08-11	Coley Pharm Group Inc	5'-CPG NUCLEIC ACIDS AND USE METHOD
AU2003300831A1 (en) *	2002-12-11	2004-06-30	Hawaii Biotech, Inc.	Recombinant vaccine against flavivirus infection
US20050287170A1 (en) *	2002-12-11	2005-12-29	Hawaii Biotech, Inc.	Subunit vaccine against West Nile viral infection
KR100525321B1 (ko) *	2002-12-13	2005-11-02	안웅식	파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
EP1625140A4 (en) *	2002-12-23	2008-06-18	Dynavax Tech Corp	BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
CN101693890B (zh) *	2002-12-23	2012-09-05	戴纳伐克斯技术股份有限公司	免疫刺激序列寡核苷酸和使用方法
WO2004060396A2 (en)	2002-12-27	2004-07-22	Chiron Corporation	Immunogenic compositions containing phospholpid
AU2003300184B8 (en)	2002-12-30	2009-12-03	3M Innovative Properties Company	Immunostimulatory combinations
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
MXPA05007295A (es)	2003-01-06	2005-09-30	Corixa Corp	Ciertos compuestos de fosfato de aminoalquil glucosaminida y su uso.
EP2192172B1 (en)	2003-02-03	2014-12-03	iBio, Inc.	System for expression of genes in plants
EP1592302A4 (en) *	2003-02-13	2007-04-25	3M Innovative Properties Co	METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
ES2385933T3 (es)	2003-02-20	2012-08-03	University Of Connecticut Health Center	Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina.
GB2398783A (en)	2003-02-26	2004-09-01	Antonio Lanzavecchia	A method for producing immortalised human B memory lymphocytes
WO2004075865A2 (en) *	2003-02-27	2004-09-10	3M Innovative Properties Company	Selective modulation of tlr-mediated biological activity
JP2006519866A (ja)	2003-03-04	2006-08-31	スリーエムイノベイティブプロパティズカンパニー	Ｕｖ誘発性の表皮の新形成の予防的治療
EP2053125B1 (en)	2003-03-04	2014-04-30	Valneva Austria GmbH	Streptococcus pyogenes antigens
WO2004080292A2 (en)	2003-03-13	2004-09-23	3M Innovative Properties Company	Method of tattoo removal
MXPA05009694A (es) *	2003-03-13	2005-10-20	3M Innovative Properties Co	Metodos para mejorar la calidad de la piel.
WO2004084938A1 (en)	2003-03-24	2004-10-07	Intercell Ag	Improved vaccines
US20040192585A1 (en) *	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
EP1605972A2 (en) *	2003-03-26	2005-12-21	Cytos Biotechnology AG	Hiv-peptide-carrier-conjugates
US20060172959A1 (en) *	2003-03-26	2006-08-03	Dan Smith	Selected rna motifs to include cell death and/or apoptosis
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
ATE449177T1 (de)	2003-03-31	2009-12-15	Intercell Ag	Staphylococcus epidermidis antigene
WO2004087203A2 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
JP2007500210A (ja) *	2003-04-10	2007-01-11	スリーエムイノベイティブプロパティズカンパニー	金属含有微粒子担体材料を使用した免疫反応調節物質化合物の送達
SE0301109D0 (sv) *	2003-04-14	2003-04-14	Mallen Huang	Nucleotide vaccine composition
CA2522238A1 (en)	2003-04-15	2004-10-28	Intercell Ag	S. pneumoniae antigens
EP1617845A4 (en) *	2003-04-28	2006-09-20	3M Innovative Properties Co	COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
CN101864431A (zh)	2003-05-07	2010-10-20	英特塞尔股份公司	无乳链球菌抗原ⅰ和ⅱ
AU2004238139B2 (en)	2003-05-15	2009-12-03	Japan Science And Technology Agency	Immunostimulating Agents
WO2005026375A2 (en)	2003-05-22	2005-03-24	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
EP1629005A2 (en)	2003-05-30	2006-03-01	Intercell AG	Enterococcus antigens
PT1631264E (pt)	2003-06-02	2009-11-03	Novartis Vaccines & Diagnostic	Composições imunogénicas à base de micropartículas biodegradáveis que compreendem um toxóide de difteria e do tétano
WO2005000884A1 (en)	2003-06-05	2005-01-06	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
MXPA05013922A (es) *	2003-06-20	2006-02-24	Coley Pharm Group Inc	Antagonistas de receptor tipo toll de molecula pequena.
US20060251623A1 (en) *	2003-07-10	2006-11-09	Caytos Biotechnology Ag	Packaged virus-like particles
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
US8221771B2 (en) *	2003-08-05	2012-07-17	3M Innovative Properties Company	Formulations containing an immune response modifier
AU2004266658A1 (en) *	2003-08-12	2005-03-03	3M Innovative Properties Company	Hydroxylamine substituted imidazo-containing compounds
US20060035242A1 (en)	2004-08-13	2006-02-16	Michelitsch Melissa D	Prion-specific peptide reagents
US20050048072A1 (en) *	2003-08-25	2005-03-03	3M Innovative Properties Company	Immunostimulatory combinations and treatments
MY145983A (en) *	2003-08-27	2012-05-31	3M Innovative Properties Co	Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2005020995A1 (en) *	2003-09-02	2005-03-10	3M Innovative Properties Company	Methods related to the treatment of mucosal associated conditions
WO2005023190A2 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for cd5+ b cell lymphoma
US8541002B2 (en)	2003-09-12	2013-09-24	Agenus Inc.	Vaccine for treatment and prevention of herpes simplex virus infection
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
ES2346314T3 (es)	2003-10-02	2010-10-14	Glaxosmithkline Biolog Sa	Antigenos de b. pertussis y uso de los mismos en vacunacion.
RU2412942C2 (ru) *	2003-10-03	2011-02-27	3М Инновейтив Пропертиз Компани	Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
CA2542099A1 (en) *	2003-10-11	2005-04-21	Inex Pharmaceuticals Corporation	Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
CN101454451A (zh) *	2003-10-30	2009-06-10	科勒制药有限公司	具有增强免疫刺激能力的c类寡核苷酸类似物
CA2543685A1 (en) *	2003-10-31	2005-05-12	3M Innovative Properties Company	Neutrophil activation by immune response modifier compounds
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
WO2005048945A2 (en) *	2003-11-14	2005-06-02	3M Innovative Properties Company	Hydroxylamine substituted imidazo ring compounds
CA2545774A1 (en)	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
KR101130928B1 (ko) *	2003-11-25	2012-04-12	쓰리엠 이노베이티브 프로퍼티즈 컴파니	치환된 이미다조 고리 시스템 및 방법
US20050277127A1 (en) *	2003-11-26	2005-12-15	Epitomics, Inc.	High-throughput method of DNA immunogen preparation and immunization
US20050287118A1 (en) *	2003-11-26	2005-12-29	Epitomics, Inc.	Bacterial plasmid with immunological adjuvant function and uses thereof
EP1689361A4 (en) *	2003-12-02	2009-06-17	3M Innovative Properties Co	THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
EP1708745B1 (en)	2003-12-23	2012-04-18	Arbor Vita Corporation	Antibodies for oncogenic strains of hpv and methods of their use
JP4817599B2 (ja) *	2003-12-25	2011-11-16	独立行政法人科学技術振興機構	免疫活性増強剤とこれを用いた免疫活性の増強方法
US8802853B2 (en) *	2003-12-29	2014-08-12	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) *	2003-12-30	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
WO2005067500A2 (en) *	2003-12-30	2005-07-28	3M Innovative Properties Company	Enhancement of immune responses
WO2005072290A2 (en) *	2004-01-23	2005-08-11	Joslin Diabetes Center	Methods of treating, reducing, or preventing autoimmune conditions
CA2555274A1 (en)	2004-02-05	2005-08-25	The Ohio State University Research Foundation	Chimeric vegf peptides
US20050181035A1 (en) *	2004-02-17	2005-08-18	Dow Steven W.	Systemic immune activation method using non CpG nucleic acids
AU2005230938A1 (en)	2004-02-19	2005-10-20	Coley Pharmaceutical Gmbh	Immunostimulatory viral RNA oligonucleotides
WO2005090968A1 (en) *	2004-03-16	2005-09-29	Inist Inc.	Tat-based immunomodulatory compositions and methods of their discovery and use
CA2559458A1 (en)	2004-03-19	2005-10-06	Xiu-Min Li	Herbal therapy for the treatment of food allergy
CA2559863A1 (en) *	2004-03-24	2005-10-13	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
AU2005244260B2 (en) *	2004-04-09	2010-08-05	3M Innovative Properties Company	Methods, compositions, and preparations for delivery of immune response modifiers
MXPA06012451A (es) *	2004-04-28	2007-01-31	3M Innovative Properties Co	Composiciones y metodos para vacunacion por la mucosa.
AU2005247341B2 (en)	2004-05-06	2008-05-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Methods and compositions for the treatment of uveitis
WO2006031264A2 (en)	2004-05-25	2006-03-23	Oregon Health And Science University	Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
AU2005294805B2 (en)	2004-05-28	2012-02-16	Oryxe	A mixture for transdermal delivery of low and high molecular weight compounds
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
WO2005123080A2 (en) *	2004-06-15	2005-12-29	3M Innovative Properties Company	Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) *	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
WO2006009826A1 (en) *	2004-06-18	2006-01-26	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US20070259881A1 (en) *	2004-06-18	2007-11-08	Dellaria Joseph F Jr	Substituted Imidazo Ring Systems and Methods
WO2006065280A2 (en) *	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
EP2484374A1 (en)	2004-07-18	2012-08-08	CSL Limited	Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1773884B1 (en)	2004-08-03	2012-03-07	Innate Pharma	Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
WO2006026470A2 (en) *	2004-08-27	2006-03-09	3M Innovative Properties Company	Hiv immunostimulatory compositions
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
WO2006032475A2 (en)	2004-09-22	2006-03-30	Glaxosmithkline Biologicals S.A.	Staphylococcal immunogenic compositions
EP2149583B1 (en)	2004-09-24	2015-10-28	Novartis AG	Modified VP1-capsid protein of parvovirus B19
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006042254A2 (en) *	2004-10-08	2006-04-20	3M Innovative Properties Company	Adjuvant for dna vaccines
CA2587084C (en)	2004-10-08	2019-07-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Modulation of replicative fitness by using less frequently used synonym ous codons
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
US7332324B2 (en)	2004-12-03	2008-02-19	University Of Toledo	Attenuated vaccine useful for immunizations against Coccidioides spp. infections
JP2008523076A (ja) *	2004-12-08	2008-07-03	スリーエムイノベイティブプロパティズカンパニー	免疫調節性の組成物、合剤、および方法
US9809824B2 (en) *	2004-12-13	2017-11-07	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
ES2392648T3 (es)	2004-12-30	2012-12-12	3M Innovative Properties Company	Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
EP1831226B1 (en)	2004-12-30	2012-08-08	3M Innovative Properties Company	Chiral tetracyclic compounds inducing interferon biosynthesis
PL1830876T3 (pl)	2004-12-30	2015-09-30	Meda Ab	Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
PT2682126T (pt)	2005-01-27	2017-02-28	Children`S Hospital & Res Center At Oakland	Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
JP2008530022A (ja)	2005-02-04	2008-08-07	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫反応調節物質を含む水性ゲル処方物
EP1846405A2 (en)	2005-02-11	2007-10-24	3M Innovative Properties Company	Oxime and hydroxylamine substituted imidazo 4,5-c ring compounds and methods
AU2006216493A1 (en) *	2005-02-24	2006-08-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligonucleotides
GB0504436D0 (en)	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US8101345B1 (en)	2005-03-25	2012-01-24	Isis Pharmaceuticals, Inc.	Proinflammatory nucleic acids
CN103372206A (zh)	2005-03-31	2013-10-30	葛兰素史密丝克莱恩生物有限公司	针对衣原体感染的疫苗
JP2008538550A (ja)	2005-04-01	2008-10-30	コーリーファーマシューティカルグループ，インコーポレイテッド	ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
JP2008535832A (ja)	2005-04-01	2008-09-04	コーリーファーマシューティカルグループ，インコーポレイテッド	ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
EP1868628B1 (en) *	2005-04-08	2014-06-11	Chimerix, Inc.	Compounds, compositions and methods for the treatment of poxvirus infections
EP1874325A2 (en) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
JP2008538354A (ja) *	2005-04-08	2008-10-23	キメリクス，インコーポレイテッド	ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
AU2006241166A1 (en) *	2005-04-25	2006-11-02	3M Innovative Properties Company	Immunostimulatory compositions
WO2006116458A2 (en) *	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhances immunostimulatory activity
EP2426141B1 (en)	2005-04-29	2014-10-01	GlaxoSmithKline Biologicals S.A.	Method for preventing or treating M tuberculosis infection
JP5220594B2 (ja)	2005-06-14	2013-06-26	プロトクスセラピューティックスインコーポレイティッド	ポア形成修飾タンパク質を用いて良性前立腺肥大症を治療または予防する方法
AU2006261342B2 (en)	2005-06-15	2012-02-02	The Ohio State University Research Foundation	Her-2 peptides
GB0513421D0 (en)	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
EP1904077B1 (en)	2005-07-01	2009-08-12	Index Pharmaceuticals AB	Modulating responsiveness to steroids
PT2269622E (pt)	2005-07-01	2014-03-20	Index Pharmaceuticals Ab	Oligonucleotídeos cpg utilizados para aumentar a actividade dos esteróides num doente dependente de esteróides
NZ565311A (en) *	2005-07-07	2009-10-30	Pfizer	Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2007008904A2 (en) *	2005-07-08	2007-01-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
CA2614884A1 (en)	2005-07-11	2007-01-18	Globeimmune, Inc	Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US8962278B2 (en)	2005-08-03	2015-02-24	Ibio Inc.	Compositions and methods for production of immunoglobulins
US20100130425A1 (en)	2005-09-09	2010-05-27	Oregon Health & Science University	Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
SG165394A1 (en) *	2005-09-16	2010-10-28	Coley Pharm Gmbh	Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
AU2006337419A1 (en) *	2005-09-16	2007-08-09	Coley Pharmaceutical Gmbh	Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
WO2007041190A2 (en) *	2005-09-30	2007-04-12	The University Of Iowa Research Foundation	Polymer-based delivery system for immunotherapy of cancer
JP2009513629A (ja)	2005-10-28	2009-04-02	インデックス・ファーマシューティカルズ・アクチエボラーグ	炎症性疾患を予防、処置、および／または緩和する組成物および方法
AU2006318464B2 (en)	2005-11-25	2011-02-17	Zoetis Belgium Sa	Immunostimulatory oligoribonucleotides
ATE534415T1 (de)	2005-12-13	2011-12-15	Harvard College	Gerüste zur zelltransplantation
NZ569741A (en)	2005-12-14	2012-02-24	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
TR201900418T4 (tr)	2005-12-22	2019-02-21	Glaxosmithkline Biologicals Sa	Pnömokok polisakkarit konjugat aşısı.
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EP1981905B1 (en)	2006-01-16	2016-08-31	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Chlamydia vaccine
CN101374859B (zh)	2006-01-17	2014-11-26	阿恩·福斯格伦	新的表面外露流感嗜血菌蛋白质(蛋白质E；pE)
EP1984405A4 (en)	2006-02-13	2010-06-30	Fraunhofer Usa Inc	INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS
PT1991678E (pt)	2006-02-15	2015-11-25	Adiutide Pharmaceuticals Gmbh	Composições e métodos para formulações de oligonucleótidos
EP3085373A1 (en)	2006-02-22	2016-10-26	3M Innovative Properties Company	Immune response modifier conjugates
BRPI0708865A8 (pt)	2006-03-14	2019-01-22	Univ Oregon Health & Science	métodos para produzir uma resposta imune à tuberculose
US20100021503A1 (en)	2006-03-30	2010-01-28	Glaxosmithkline Biologicals S.A.	Immunogenic composition
JPWO2007119815A1 (ja)	2006-04-14	2009-08-27	協和発酵キリン株式会社	Ｔｏｌｌ様受容体９作動薬
CA2653939C (en)	2006-05-31	2013-01-22	Toray Industries, Inc.	Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
EP2258874B1 (en)	2006-06-02	2015-03-18	GlaxoSmithKline Biologicals S.A.	Method for identifying whether a patient will be responder or not to immunotherapy
KR100906970B1 (ko)	2006-06-03	2009-07-10	주식회사 바이오씨에스	피부 면역질환에 대한 ＣｐＧ 올리고데옥시뉴클레오티드의치료학적 용도
WO2007143582A2 (en) *	2006-06-05	2007-12-13	Baylor College Of Medicine	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
WO2007144150A1 (en)	2006-06-12	2007-12-21	Cytos Biotechnology Ag	Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
JP5275982B2 (ja)	2006-06-12	2013-08-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
EP2292645A3 (en)	2006-07-07	2011-05-25	Intercell AG	Small Streptococcus pyogenes antigens and their use
US8153116B2 (en)	2006-07-11	2012-04-10	University Of Connecticut	Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) *	2006-07-11	2012-03-06	University Of Connecticut	Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US7906506B2 (en) *	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
EP2046954A2 (en)	2006-07-31	2009-04-15	Curevac GmbH	NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
CN103585624A (zh)	2006-09-07	2014-02-19	葛兰素史密丝克莱恩生物有限公司	疫苗
CA2661224A1 (en)	2006-09-15	2008-03-20	Intercell Ag	Borrelia antigens
DK2468300T3 (da)	2006-09-26	2018-01-29	Infectious Disease Res Inst	Vaccinesammensætning indeholdende syntetisk adjuvant
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
NZ575437A (en) *	2006-09-27	2012-02-24	Coley Pharm Gmbh	Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
CN101558157A (zh) *	2006-10-26	2009-10-14	科勒制药有限责任公司	寡核糖核苷酸及其应用
DK3029461T3 (en) *	2006-11-01	2018-02-05	Ventana Med Syst Inc	Haptenes, hapten conjugates, compositions thereof and processes for their preparation and use
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
CA2669137A1 (en) *	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
CA2675379A1 (en)	2007-01-12	2008-07-17	Intercell Ag	Protective proteins of s. agalactiae, combinations thereof and methods of using the same
AU2008221383B2 (en)	2007-02-28	2012-09-13	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
CN103550764A (zh)	2007-03-02	2014-02-05	葛兰素史密丝克莱恩生物有限公司	疫苗组合物及其在刺激免疫反应中的用途
US20090041809A1 (en) *	2007-03-07	2009-02-12	Nventa Biopharmaceuticals Corporation	Double-stranded locked nucleic acid compositions
BRPI0809247A2 (pt)	2007-03-19	2014-09-09	Globeimmune Inc	Composições e métodos para a ablação do escape mutacional de terapias marcadas para câncer.
MX351247B (es)	2007-04-04	2017-10-05	Infectious Disease Res Institute Star	Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
US9452209B2 (en)	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
US8778348B2 (en)	2007-04-28	2014-07-15	Ibio Inc.	Trypanosoma antigens, vaccine compositions, and related methods
EP2497779A1 (en)	2007-05-02	2012-09-12	Intercell AG	Klebsiella antigens
AU2008248640A1 (en)	2007-05-02	2008-11-13	Glaxosmithkline Biologicals S.A.	Vaccine
WO2008136748A1 (en) *	2007-05-04	2008-11-13	Index Pharmaceuticals Ab	Tumour growth inhibitory compounds and methods of their use
AU2008252577A1 (en) *	2007-05-17	2008-11-27	Coley Pharmaceutical Gmbh	Class A oligonucleotides with immunostimulatory potency
PL2170353T3 (pl) *	2007-05-18	2015-10-30	Adiutide Pharmaceuticals Gmbh	Modyfikowane fosforanami analogi oligonukleotydów wykazujące aktywność immunostymulującą
WO2008153744A2 (en)	2007-05-23	2008-12-18	Ventana Medical Systems, Inc.	Polymeric carriers for immunohistochemistry and in situ hybridization
CL2008001491A1 (es)	2007-05-24	2008-11-28	Glaxosmithkline Biolog Sa	Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
WO2008145400A2 (en)	2007-05-31	2008-12-04	Medigene Ag	Mutated structural protein of a parvovirus
EP2012122A1 (en)	2007-07-06	2009-01-07	Medigene AG	Mutated parvovirus structural proteins as vaccines
AU2008265218A1 (en)	2007-06-18	2008-12-24	Intercell Ag	Chlamydia antigens
KR101579947B1 (ko)	2007-06-26	2015-12-28	글락소스미스클라인 바이오로지칼즈 에스.에이.	스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
WO2009006479A2 (en)	2007-07-02	2009-01-08	Etubics Corporation	Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
US8404252B2 (en)	2007-07-11	2013-03-26	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
KR101580660B1 (ko)	2007-08-02	2015-12-28	바이오앤드백스 파마슈티칼즈, 리미티드.	다중체 다중-에피토프 인플루엔자 백신
JP2010535504A (ja)	2007-08-03	2010-11-25	プレジデントアンドフェロウズオブハーバードカレッジ	クラミジア抗原
US7879812B2 (en)	2007-08-06	2011-02-01	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides and methods of use therefor
UY31285A1 (es)	2007-08-13	2009-03-31		Vacunas
CN101835487A (zh) *	2007-08-21	2010-09-15	戴纳瓦克斯技术公司	制备和使用流感蛋白质的组合物和方法
US9370531B2 (en) *	2007-08-31	2016-06-21	New York University	Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
MX2010002965A (es)	2007-09-17	2010-09-14	Oncomethylome Sciences Sa	Deteccion mejorada de la expresion de mage-a.
KR20100068422A (ko)	2007-10-09	2010-06-23	콜리 파마슈티칼 게엠베하	변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
ES2445755T3 (es)	2007-11-07	2014-03-05	Celldex Therapeutics, Inc.	Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
JP2011514881A (ja)	2007-11-09	2011-05-12	ザソルクインスティテュートフォーバイオロジカルスタディーズ	免疫増強剤としてのｔａｍ受容体阻害剤の使用および免疫抑制剤としてのｔａｍ活性化剤の使用
AU2008331800A1 (en)	2007-12-03	2009-06-11	President And Fellows Of Harvard College	Chlamydia antigens
ES2664753T3 (es)	2007-12-07	2018-04-23	Glaxosmithkline Biologicals Sa	Composiciones de inducción de respuestas inmunes
LT2222710T (lt)	2007-12-24	2016-12-12	Id Biomedical Corporation Of Quebec	Rekombinantiniai rsv antigenai
WO2009094191A2 (en) *	2008-01-25	2009-07-30	Chimerix, Inc.	Methods of treating viral infections
KR101483715B1 (ko)	2008-01-31	2015-01-19	큐어백 게엠바하	면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
WO2009102465A2 (en)	2008-02-13	2009-08-20	President And Fellows Of Harvard College	Continuous cell programming devices
US10383887B2 (en) *	2008-02-20	2019-08-20	New York University	Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US9511131B2 (en)	2008-03-10	2016-12-06	Children's Hospital & Research Center Oakland	Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
JP2011514167A (ja)	2008-03-17	2011-05-06	インターセルアーゲー	肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
JP2011518186A (ja)	2008-04-18	2011-06-23	ザジェネラルホスピタルコーポレイション	自己集合性ワクチンを使用する免疫療法
JP5727367B2 (ja) *	2008-05-15	2015-06-03	ダイナバックステクノロジーズコーポレイション	免疫賦活オリゴヌクレオチドを使用する長期疾患改良
WO2009143292A2 (en)	2008-05-21	2009-11-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating pneumoconiosis with oligodeoxynucleotides
CA2826508C (en)	2008-05-23	2016-07-19	The Regents Of The University Of Michigan	Nanoemulsion vaccines
US8703490B2 (en)	2008-06-05	2014-04-22	Ventana Medical Systems, Inc.	Compositions comprising nanomaterials and method for using such compositions for histochemical processes
TWI351288B (en) *	2008-07-04	2011-11-01	Univ Nat Pingtung Sci & Tech	Cpg dna adjuvant in avian vaccines
KR101707569B1 (ko)	2008-08-01	2017-02-16	감마 백신즈 피티와이 리미티드	인플루엔자 백신
US8658350B2 (en)	2008-09-22	2014-02-25	Oregon Health & Science University	Methods for detecting Mycobacterium tuberculosis disease
WO2010036938A2 (en)	2008-09-26	2010-04-01	Nanobio Corporation	Nanoemulsion therapeutic compositions and methods of using the same
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
BRPI0920240B8 (pt)	2008-10-16	2021-05-25	Univ Dalhousie	composição adjuvante
WO2010048572A1 (en)	2008-10-23	2010-04-29	Cornell University	A novel anti-viral method
WO2010048731A1 (en) *	2008-10-31	2010-05-06	Christopher John Ong	Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
US9974844B2 (en)	2008-11-17	2018-05-22	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
ES2866623T3 (es)	2008-11-24	2021-10-19	Massachusetts Inst Technology	Métodos y composiciones para el suministro localizado de nanopartículas a un tumor
RU2572826C2 (ru)	2008-12-02	2016-01-20	Чиралджен, Лтд.	Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
EP2356225A1 (en)	2008-12-03	2011-08-17	Protea Vaccine Technologies Ltd.	GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
CA2745603A1 (en)	2008-12-03	2010-06-10	Proyecto De Biomedicina Cima, S.L.	Use of phenol soluble modulins for the development of vaccines
WO2010067262A1 (en)	2008-12-09	2010-06-17	Pfizer Inc.	Immunostimulatory oligonucleotides
EP2865389A1 (en)	2008-12-09	2015-04-29	Pfizer Vaccines LLC	IgE CH3 peptide vaccine
US8552165B2 (en) *	2008-12-09	2013-10-08	Heather Davis	Immunostimulatory oligonucleotides
WO2010078556A1 (en)	2009-01-05	2010-07-08	Epitogenesis Inc.	Adjuvant compositions and methods of use
WO2010084100A1 (en)	2009-01-20	2010-07-29	Transgene Sa	Soluble icam-1 as biomarker for prediction of therapeutic response
US20100234283A1 (en)	2009-02-04	2010-09-16	The Ohio State University Research Foundation	Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
WO2010089340A2 (en)	2009-02-05	2010-08-12	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en)	2009-02-13	2012-01-18	Intercell AG	Nontypable haemophilus influenzae antigens
US8664183B2 (en)	2009-02-27	2014-03-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	SPANX-B polypeptides and their use
EP2408933A2 (en)	2009-03-17	2012-01-25	MDxHealth SA	Improved detection of gene expression
DK2411043T3 (da)	2009-03-23	2013-10-21	Pin Pharma Inc	Behandling af cancer med immunostimulatorisk hiv tat derivat-polypeptider
JP5774578B2 (ja)	2009-03-24	2015-09-09	トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅＳ．Ａ．	患者をモニターするためのバイオマーカー
US20120100173A1 (en)	2009-04-03	2012-04-26	Agenus Inc.	Methods for preparing and using multichaperone-antigen complexes
NZ594896A (en)	2009-04-17	2013-07-26	Transgene Sa	Biomarker for monitoring patients
CN102686244A (zh) *	2009-04-21	2012-09-19	西莱克塔生物科技公司	提供一种Th1-偏向性应答的免疫纳米疗法
MX340830B (es)	2009-04-30	2016-07-26	Coley Pharm Group Inc	Vacuna neumococica y usos de la misma.
JP2012528106A (ja)	2009-05-27	2012-11-12	グラクソスミスクラインバイオロジカルズソシエテアノニム	Ｃａｓｂ７４３９構築物
EP2435095A2 (en)	2009-05-27	2012-04-04	Selecta Biosciences, Inc.	Immunomodulatory agent-polymeric compounds
TWI494125B (zh)	2009-06-05	2015-08-01	Infectious Disease Res Inst	合成的葡萄吡喃糖基脂質佐劑
CN102596243B (zh)	2009-06-16	2015-10-21	密执安大学评议会	纳米乳剂疫苗
MX2012000036A (es)	2009-06-24	2012-02-28	Glaxosmithkline Biolog Sa	Vacuna.
MX2012000035A (es)	2009-06-24	2012-02-28	Id Biomedical Corp Quebec	Antigenos de virus de sincicio respiratorio recombinantes.
SG10201403841QA (en)	2009-07-06	2014-09-26	Ontorii Inc	Novel nucleic acid prodrugs and methods of use thereof
WO2011003905A1 (en)	2009-07-10	2011-01-13	Transgene Sa	Biomarker for selecting patients and related methods
AR077757A1 (es)	2009-07-15	2011-09-21	Novartis Ag	Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
WO2011011519A1 (en)	2009-07-21	2011-01-27	Chimerix, Inc.	Compounds, compositions and methods for treating ocular conditions
WO2011013034A1 (en)	2009-07-30	2011-02-03	Pfizer Vaccines Llc	Antigenic tau peptides and uses thereof
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
EP2471801A4 (en)	2009-08-26	2013-12-04	Rna Inc	GLYCOLIPIDES DERIVED FROM LIPOTHEICHOIC ACID AND COMPOSITIONS CONTAINING THESE GLYCOLIPIDS
WO2011026111A1 (en)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oral delivery of a vaccine to the large intestine to induce mucosal immunity
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CN104548089B (zh)	2009-09-03	2017-09-26	辉瑞疫苗有限责任公司	Pcsk9疫苗
CN102573886A (zh) *	2009-09-17	2012-07-11	相互制药公司	用抗病毒剂治疗哮喘的方法
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
EP2483307A1 (en)	2009-09-29	2012-08-08	Fraunhofer USA, Inc.	Influenza hemagglutinin antibodies, compositions, and related methods
ES2594485T3 (es)	2009-10-07	2016-12-20	Uvic Industry Partnerships Inc.	Vacunas que comprenden transgenes sensibles al calor
EP2308896A1 (en)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
US20120282637A1 (en)	2009-10-09	2012-11-08	Sanofi	Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving
EP2319871A1 (en)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
WO2011047340A1 (en)	2009-10-16	2011-04-21	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0919117D0 (en)	2009-10-30	2009-12-16	Glaxosmithkline Biolog Sa	Process
WO2011063263A2 (en)	2009-11-20	2011-05-26	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
SG10201408505SA (en)	2009-12-22	2015-02-27	Celldex Therapeutics Inc	Vaccine compositions
FR2954703B1 (fr)	2009-12-28	2013-12-13	Chu Nantes	Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
HUE032860T2 (en)	2010-02-12	2017-11-28	Chimerix Inc	A method for treating a virus infection
WO2011101332A1 (en)	2010-02-16	2011-08-25	Proyecto De Biomedicina Cima, S.L.	Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
US8685416B2 (en)	2010-03-02	2014-04-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of cancer
WO2011109833A2 (en)	2010-03-05	2011-09-09	President And Fellows Of Harvard College	Induced dendritic cell compositions and uses thereof
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
JP2013521326A (ja)	2010-03-10	2013-06-10	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物
WO2011112599A2 (en)	2010-03-12	2011-09-15	The United States Of America, As Represented By The Secretary. Department Of Health & Human Services	Immunogenic pote peptides and methods of use
RU2595872C2 (ru)	2010-03-19	2016-08-27	Массачусетс Интитут Оф Текнолоджи	Композиции липидных везикул и способы применения
US9149432B2 (en)	2010-03-19	2015-10-06	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
US20110229556A1 (en) *	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid-coated polymer particles for immune stimulation
GB201005005D0 (en)	2010-03-25	2010-05-12	Angeletti P Ist Richerche Bio	New vaccine
BR122021020829B8 (pt)	2010-03-30	2022-12-27	Children´S Hospital & Res Center At Oakland	Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
JP6002659B2 (ja)	2010-04-13	2016-10-05	セルデックス・セラピューティクス・インコーポレイテッド	ヒトｃｄ２７に結合する抗体およびその使用
AU2011248620B2 (en)	2010-04-26	2015-11-26	Chimerix, Inc.	Methods of treating retroviral infections and related dosage regimes
NO2772265T3 (pt)	2010-05-14	2018-06-16
BR112012029912A2 (pt)	2010-05-26	2016-11-16	Selecta Biosciences Inc	vácinas de combinação de nanotransportadores sintéticos
LT2575878T (lt)	2010-05-28	2018-11-12	Zoetis Belgium S.A.	Vakcinos, apimančios cholesterolio ir cpg, kaip vienintelio adjuvanto-nešiklio, molekules
EP2575868A1 (en)	2010-06-07	2013-04-10	Pfizer Vaccines LLC	Ige ch3 peptide vaccine
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
ES2558106T3 (es)	2010-07-30	2016-02-02	Curevac Ag	Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
AU2011298306B2 (en)	2010-09-03	2017-10-19	Valneva Austria Gmbh	Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
CA2811103C (en)	2010-09-14	2020-01-14	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Computationally optimized broadly reactive antigens for influenza
EP2620428B1 (en)	2010-09-24	2019-05-22	Wave Life Sciences Ltd.	Asymmetric auxiliary group
WO2012041669A1 (en)	2010-09-27	2012-04-05	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
PT2624873T (pt)	2010-10-06	2020-03-04	Harvard College	Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
US20130345079A1 (en)	2010-10-27	2013-12-26	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
WO2012061717A1 (en)	2010-11-05	2012-05-10	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
ES2859673T3 (es)	2010-11-08	2021-10-04	Infectious Disease Res Inst	Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
PH12013501204A1 (en)	2010-12-14	2013-07-29	Glaxosmithkline Biologicals Sa	Mycobacterium antigenic composition
AU2012211043B2 (en)	2011-01-27	2017-04-06	Gamma Vaccines Pty Limited	Combination vaccines
CA2828068C (en)	2011-02-22	2019-03-19	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012131504A1 (en)	2011-03-02	2012-10-04	Pfizer Inc.	Pcsk9 vaccine
EP2505640A1 (en)	2011-03-29	2012-10-03	Neo Virnatech, S.L.	Vaccine compositions for birnavirus-borne diseases
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
SG194083A1 (en)	2011-04-08	2013-11-29	Immune Design Corp	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
US20120288515A1 (en)	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
LT2707385T (lt)	2011-05-13	2017-12-11	Glaxosmithkline Biologicals Sa	Iš anksto sulieti rsv f antigenai
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
WO2012167053A1 (en)	2011-06-01	2012-12-06	Janus Biotherapeutics, Inc.	Novel immune system modulators
WO2012167046A1 (en)	2011-06-01	2012-12-06	Janus Biotherapeutics, Inc.	Novel immune system modulators
CA2838158C (en)	2011-06-03	2019-07-16	3M Innovative Properties Company	Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
CA2838023C (en)	2011-06-03	2019-08-13	3M Innovative Properties Company	Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
US20130156803A1 (en)	2011-06-04	2013-06-20	Rochester General Hospital Research Institute	Compositions and methods related to p6
US11673926B2 (en)	2011-06-07	2023-06-13	Ibio, Inc.	In vivo de-glycosylation of recombinant proteins by co-expression with PNGase F
US8697085B2 (en)	2011-06-17	2014-04-15	University Of Tennessee Research Foundation	Group A Streptococcus multivalent vaccine
US9580475B2 (en)	2011-06-20	2017-02-28	University of Pittsburgh—of the Commonwealth System of Higher Education	Computationally optimized broadly reactive antigens for H1N1 influenza
MX2013013627A (es)	2011-06-21	2014-04-25	Oncofactor Corp	Composiciones y metodos para la terapia y diagnostico de cancer.
WO2013007703A1 (en) *	2011-07-08	2013-01-17	Universität Zürich	CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
JP2014521687A (ja)	2011-07-29	2014-08-28	セレクタバイオサイエンシーズインコーポレーテッド	体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
GB201114919D0 (en)	2011-08-30	2011-10-12	Glaxosmithkline Biolog Sa	Method
US20140348865A1 (en)	2011-09-12	2014-11-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser.	Immunogens based on an hiv-1 v1v2 site-of-vulnerability
PE20141547A1 (es)	2011-09-16	2014-10-25	Ucb Pharma Sa	Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
PT2572725E (pt)	2011-09-21	2015-10-20	Ruprecht Karls Universität Heidelberg	Péptidos frameshift específicos de ims para a prevenção e tratamento do cancro¿
WO2013049535A2 (en)	2011-09-30	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Influenza vaccine
EP2763677B1 (en)	2011-10-04	2020-02-26	Janus Biotherapeutics, Inc.	Novel imidazole quinoline-based immune system modulators
AU2012326079B2 (en)	2011-10-20	2017-01-12	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
US20130122038A1 (en)	2011-11-14	2013-05-16	The United States Of America As Represented By The Secretary Of The Department	Heterologous prime-boost immunization using measles virus-based vaccines
EP2596806A1 (en)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Method for prevention of colectomy
SG10201605350UA (en)	2012-01-16	2016-08-30	Mckenna Elizabeth	Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
RU2018113521A (ru)	2012-02-07	2019-03-04	Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн	Рекомбинантный полипептид гемагглютинин (ha) вируса гриппа для вызова иммунного ответа в отношении вирусов гриппа h2n2 или b
WO2013119856A1 (en)	2012-02-07	2013-08-15	Infectious Disease Research Institute	Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
EP3305806B1 (en)	2012-02-13	2020-08-26	University of Pittsburgh - Of the Commonwealth System of Higher Education	Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
CA2866185C (en)	2012-03-23	2021-04-06	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
WO2013150518A1 (en)	2012-04-01	2013-10-10	Rappaport Family Institute For Research In The Medical Sciences	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
CA2870309C (en)	2012-04-16	2024-02-20	President And Fellows Of Harvard College	Mesoporous silica compositions for modulating immune responses
WO2013163176A1 (en)	2012-04-23	2013-10-31	Allertein Therapeutics, Llc	Nanoparticles for treatment of allergy
PE20142406A1 (es)	2012-05-04	2015-01-23	Pfizer	Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
JP6619648B2 (ja)	2012-05-16	2019-12-11	イミューンデザインコーポレイション	Ｈｓｖ−２のためのワクチン
EP2666785A1 (en)	2012-05-23	2013-11-27	Affiris AG	Complement component C5a-based vaccine
WO2013177291A1 (en)	2012-05-23	2013-11-28	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof
US9427476B2 (en)	2012-05-24	2016-08-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Multivalent meningococcal conjugates and methods for preparing conjugates
WO2013192144A2 (en)	2012-06-19	2013-12-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Rift valley fever virus replicon particles and use thereof
BR112015000784A8 (pt)	2012-07-13	2018-04-03	Wave Life Sciences Japan	Grupo auxiliar assimétrico
MX356830B (es)	2012-07-13	2018-06-15	Shin Nippon Biomedical Laboratories Ltd	Adyuvante de acido nucleico quiral.
CN112007045A (zh)	2012-07-13	2020-12-01	波涛生命科学有限公司	手性控制
HUE065746T2 (hu)	2012-08-03	2024-06-28	Access To Advanced Health Inst	Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
SG11201500573RA (en)	2012-08-06	2015-02-27	Glaxosmithkline Biolog Sa	Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
US9605276B2 (en)	2012-08-24	2017-03-28	Etubics Corporation	Replication defective adenovirus vector in vaccination
EP2703483A1 (en)	2012-08-29	2014-03-05	Affiris AG	PCSK9 peptide vaccine
EP3639851A1 (en)	2012-09-04	2020-04-22	Bavarian Nordic A/S	Methods and compositions for enhancing vaccine immune responses
US10232035B2 (en)	2012-09-14	2019-03-19	The Regents Of The University Of Colorado, A Body Corporate	Conditionally replication deficient herpes virus and use thereof in vaccines
WO2014043518A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
BR112015006264A2 (pt)	2012-09-21	2017-07-04	Mckenna Elizabeth	composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas
EP3859004A1 (en)	2012-10-24	2021-08-04	Platelet Targeted Therapeutics LLC	Platelet targeted treatment
WO2014090265A1 (en)	2012-12-13	2014-06-19	Ruprecht-Karls-Universität Heidelberg	Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
WO2014107663A2 (en)	2013-01-07	2014-07-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for treating cutaneous t cell lymphoma
EP2948469A4 (en)	2013-01-23	2016-11-02	Univ Leland Stanford Junior	STABILIZED HEPATITIS B CORE POLYPEPTIDE
JP6703475B2 (ja)	2013-03-13	2020-06-03	アメリカ合衆国	融合前ｒｓｖｆタンパク質およびそれらの使用
UY35418A (es)	2013-03-15	2014-10-31	Glaxosmithkline Biolog Sa	Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
EP2978447B1 (en)	2013-03-28	2019-05-08	Infectious Disease Research Institute	Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP2981285B1 (en)	2013-04-03	2020-06-03	N-Fold Llc	Novel nanoparticle compositions
SG11201508092YA (en)	2013-04-18	2015-10-29	Immune Design Corp	Gla monotherapy for use in cancer treatment
WO2014172661A1 (en)	2013-04-19	2014-10-23	The Regent Of The University Of California	Lone star virus
EP3689375A1 (en)	2013-05-15	2020-08-05	The Governors Of The University Of Alberta	E1e2 hcv vaccines and methods of use
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en)	2013-06-05	2013-07-17	Glaxosmithkline Biolog Sa	Immunogenic composition for use in therapy
WO2014201245A1 (en)	2013-06-12	2014-12-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CA2919268C (en)	2013-07-25	2023-09-05	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US9919029B2 (en)	2013-07-26	2018-03-20	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of bacterial infections
KR20160040290A (ko)	2013-08-05	2016-04-12	글락소스미스클라인 바이오로지칼즈 에스.에이.	조합 면역원성 조성물
AU2014310934B2 (en)	2013-08-21	2019-09-12	CureVac SE	Respiratory syncytial virus (RSV) vaccine
EP3049114B1 (en)	2013-09-27	2021-11-10	Massachusetts Institute of Technology	Carrier-free biologically-active protein nanostructures
ES2957209T3 (es)	2013-09-30	2024-01-15	Triad Nat Security Llc	Polipéptidos inmunogénicos mosaicos del VIH de región conservada
EP3052127A1 (en)	2013-10-04	2016-08-10	PIN Pharma, Inc.	Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
WO2015063611A2 (en)	2013-11-01	2015-05-07	University Of Oslo	Albumin variants and uses thereof
JP2016535989A (ja)	2013-11-01	2016-11-24	ファイザー・インク	前立腺関連抗原を発現させるためのベクター
WO2015070207A2 (en)	2013-11-11	2015-05-14	The Government Of The United States, As Represented By The Secretary Of The Army	Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
US9993541B2 (en)	2013-11-13	2018-06-12	University Of Oslo	Outer membrane vesicles and uses thereof
US11452767B2 (en)	2013-11-15	2022-09-27	Oslo Universitetssykehus Hf	CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Grass pollen immunogens and methods and uses for immune response modulation
CA2931112A1 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Pan pollen immunogens and methods and uses for immune response modulation
UA127337C2 (uk)	2013-11-28	2023-07-26	Баваріан Нордік А/С	Рекомбінантний поксвірус для індукції посиленої імунної відповіді та його застосування
EP3079716B1 (en)	2013-12-13	2019-05-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Multi-epitope tarp peptide vaccine and uses thereof
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
MX2016008640A (es)	2013-12-31	2016-10-07	Infectious Disease Res Inst	Formulaciones de vacuna de vial unico.
JPWO2015108047A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) *	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
CN106068325B (zh)	2014-01-16	2021-07-09	波涛生命科学有限公司	手性设计
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HUE055408T2 (hu)	2014-01-21	2021-12-28	Pfizer	Streptococcus pneumoniae kapszuláris poliszacharidok és konjugátumaik
KR102229568B1 (ko)	2014-01-21	2021-03-18	화이자 인코포레이티드	스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
DK3096785T3 (da)	2014-01-21	2020-09-21	Pfizer	Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf
MX2016009464A (es)	2014-01-21	2017-01-16	Immune Design Corp	Composiciones para el uso en el tratamiento de afecciones alergicas.
WO2015123291A1 (en)	2014-02-11	2015-08-20	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Pcsk9 vaccine and methods of using the same
TW201620927A (zh)	2014-02-24	2016-06-16	葛蘭素史密斯克藍生物品公司	Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en)	2014-02-28	2015-09-03	Alk-Abelló A/S	Polypeptides derived from phl p and methods and uses thereof for immune response modulation
US10369216B2 (en)	2014-04-01	2019-08-06	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US10111948B2 (en)	2014-04-25	2018-10-30	Tria Bioscience Corp.	Synthetic hapten carrier compositions and methods
EP3137105A4 (en)	2014-04-30	2017-12-27	President and Fellows of Harvard College	Combination vaccine devices and methods of killing cancer cells
EP3149479A2 (en)	2014-05-30	2017-04-05	Sanofi Pasteur Inc.	Expression and conformational analysis of engineered influenza hemagglutinin
EP2952893A1 (en)	2014-06-04	2015-12-09	Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)	Method for detecting antibody-secreting B cells specific for HLA
PL3164113T3 (pl)	2014-06-04	2019-09-30	Exicure, Inc.	Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych
CA2951430A1 (en)	2014-06-13	2015-12-17	Glaxosmithkline Biologicals Sa	Immunogenic combinations
WO2016011083A1 (en)	2014-07-15	2016-01-21	Immune Design Corp.	Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
CN106715458A (zh)	2014-07-18	2017-05-24	华盛顿大学	癌症疫苗组合物及其使用方法
AR101256A1 (es)	2014-07-21	2016-12-07	Sanofi Pasteur	Composición vacunal que comprende ipv y ciclodextrinas
JP2017525711A (ja)	2014-08-22	2017-09-07	ジャナスバイオセラピューティクス，インク．	新規なｎ２，ｎ４，ｎ７，６−四置換プテリジン−２，４，７−トリアミンおよび２，４，６，７−四置換プテリジン化合物ならびにその合成方法および使用
SG11201702656WA (en)	2014-10-06	2017-04-27	Exicure Inc	Anti-tnf compounds
US11083788B2 (en)	2014-10-10	2021-08-10	The Regents Of The University Of Michigan	Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AR102547A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en)	2014-11-07	2016-05-26	Takeda Vaccines, Inc.	Hand, foot, and mouth vaccines and methods of manufacture and use thereof
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US20170281744A1 (en)	2014-12-10	2017-10-05	Glaxosmithkline Biologicals Sa	Method of treatment
WO2016097865A1 (en)	2014-12-19	2016-06-23	Regenesance B.V.	Antibodies that bind human c6 and uses thereof
ES2856844T3 (es)	2014-12-31	2021-09-28	Checkmate Pharmaceuticals Inc	Inmunoterapia antitumoral combinada
JP6647315B2 (ja)	2015-01-09	2020-02-14	イーチュービクスコーポレイション	組み合わせ免疫療法のための方法および組成物
SI3244917T1 (sl)	2015-01-15	2023-07-31	Pfizer Inc.	Imunogenske kompozicije za uporabo v pnevmokoknih cepivih
CA3012602A1 (en)	2015-01-30	2016-08-04	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
WO2016131048A1 (en)	2015-02-13	2016-08-18	Icahn School Of Medicine At Mount Sinai	Rna containing compositions and methods of their use
US10813993B2 (en)	2015-03-03	2020-10-27	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Display platform from bacterial spore coat proteins
WO2016141320A2 (en)	2015-03-05	2016-09-09	Northwestern University	Non-neuroinvasive viruses and uses thereof
US20180044429A1 (en)	2015-03-09	2018-02-15	Celldex Therapeutics, Inc.	Cd27 agonists
EP3270897A4 (en)	2015-03-20	2018-12-05	The Regents Of The University Of Michigan	Immunogenic compositions for use in vaccination against bordetella
EP3273989B1 (en)	2015-03-26	2023-12-27	Gpn Vaccines Pty Ltd	Streptococcal vaccine
EP3280464A4 (en)	2015-04-10	2018-09-26	President and Fellows of Harvard College	Immune cell trapping devices and methods for making and using the same
EP3286213B1 (en)	2015-04-20	2021-08-04	Etubics Corporation	Methods and compositions for combination immunotherapy
WO2016180852A1 (en)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing antigen-specific t cells from an umbilical cord blood sample
CA2984643A1 (en)	2015-05-13	2016-11-17	Agenus Inc.	Vaccines for treatment and prevention of cancer
US10682314B2 (en)	2015-05-26	2020-06-16	Ohio State Innovation Foundation	Nanoparticle based vaccine strategy against swine influenza virus
AU2016270979B2 (en)	2015-06-02	2020-11-12	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US10954492B2 (en)	2015-06-10	2021-03-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Processes for production and purification of nucleic acid-containing compositions
RU2018102915A (ru) *	2015-06-26	2019-07-29	Байер Энимэл Хельс ГмбХ	Способы модуляции контрольных молекул цитозольной днк
EP3325008A1 (en)	2015-07-21	2018-05-30	Pfizer Inc	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017027843A1 (en)	2015-08-12	2017-02-16	Massachusetts Institute Of Technology	Cell surface coupling of nanoparticles
EP3341017B1 (en)	2015-08-25	2024-10-16	Babita Agrawal	Immunomodulatory compositions comprising caulobacter crescentus and use thereof
US11260018B2 (en)	2015-09-17	2022-03-01	Jrx Biotechnology, Inc.	Approaches for improving skin hydration and moisturization
US10526309B2 (en)	2015-10-02	2020-01-07	The University Of North Carolina At Chapel Hill	Pan-TAM inhibitors and Mer/Axl dual inhibitors
EP3359651A1 (en)	2015-10-05	2018-08-15	THE UNITED STATES OF AMERICA, represented by the S	Human rota virus g9p[6]strain and use as a vaccine
JP7098519B2 (ja)	2015-10-08	2022-07-11	ザガバナーズオブザユニバーシティオブアルバータ	Ｃ型肝炎ウイルスｅ１／ｅ２ヘテロダイマー及びそれを生成する方法
GB201518668D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Immunogenic Comosition
AU2016343845B2 (en)	2015-10-30	2023-04-13	Baylor College Of Medicine	Compositions and methods for the treatment of HER2-expressing solid tumors
JP6884145B2 (ja)	2015-11-20	2021-06-09	ファイザー・インク	肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
WO2017120504A1 (en)	2016-01-08	2017-07-13	Durfee Paul N	Osteotropic nanoparticles for prevention or treatment of bone metastases
HUE059343T2 (hu)	2016-01-29	2022-11-28	Bavarian Nordic As	Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag
JP7138864B2 (ja)	2016-02-06	2022-09-20	プレジデントアンドフェローズオブハーバードカレッジ	免疫を再構成するための造血ニッチの再現
WO2017156461A2 (en)	2016-03-10	2017-09-14	Aperisys, Inc.	Antigen-binding fusion proteins with modified hsp70 domains
EP3430039A1 (en)	2016-03-14	2019-01-23	Universitetet I Oslo	Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en)	2016-03-14	2017-09-21	University Of Oslo	Anti-viral engineered immunoglobulins
EP3436066A1 (en)	2016-04-01	2019-02-06	Checkmate Pharmaceuticals, Inc.	Fc receptor-mediated drug delivery
JP7038064B2 (ja)	2016-04-18	2022-03-17	セルデックスセラピューティクスインコーポレイテッド	ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
WO2017189448A1 (en)	2016-04-25	2017-11-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bivalent immunogenic conjugate for malaria and typhoid
ES2929054T3 (es)	2016-05-16	2022-11-24	Access To Advanced Health Inst	Formulación que contiene un agonista de TLR y métodos de uso
WO2017201390A1 (en)	2016-05-19	2017-11-23	The Regents Of The University Of Michigan	Novel adjuvant compositions
MX2018014270A (es)	2016-05-21	2019-02-14	Infectious Disease Res Inst	Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
CN109890408A (zh)	2016-05-27	2019-06-14	埃特彼塞斯公司	新表位疫苗组合物及其使用方法
IL315825A (en)	2016-06-01	2024-11-01	Access To Advanced Health Inst	Nanoalum particles containing a fixing factor
AU2017272344B2 (en)	2016-06-02	2022-03-03	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
SG10201913650WA (en)	2016-06-03	2020-03-30	Sanofi Pasteur Inc	Modification of engineered influenza hemagglutinin polypeptides
US11472856B2 (en)	2016-06-13	2022-10-18	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
CA3026807A1 (en)	2016-06-13	2017-12-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
US11780924B2 (en)	2016-06-21	2023-10-10	University Of Oslo	HLA binding vaccine moieties and uses thereof
WO2018009604A1 (en)	2016-07-08	2018-01-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric dengue/zika viruses live-attenuated zika virus vaccines
WO2018009603A1 (en)	2016-07-08	2018-01-11	The United State of America, as represented by the Secretary, Department of Health and Human Service	Chimeric west nile/zika viruses and methods of use
MA45738A (fr)	2016-07-13	2019-05-22	Harvard College	Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser
SG11201900794PA (en)	2016-08-05	2019-02-27	Sanofi Pasteur Inc	Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3493840B1 (en)	2016-08-05	2022-08-24	Sanofi Pasteur Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
CN109863169A (zh)	2016-08-23	2019-06-07	葛兰素史密丝克莱恩生物有限公司	具有连接至不变链(cd74)的短片段的抗原的融合肽
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
BR112019004913B1 (pt)	2016-09-16	2022-07-12	Infectious Disease Research Institute	Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
EP3518966A1 (en)	2016-09-29	2019-08-07	GlaxoSmithKline Biologicals S.A.	Compositions and methods of treatment of persistent hpv infection
JP7146777B2 (ja) *	2016-10-07	2022-10-04	セカルナ・ファーマシューティカルズ・ゲーエムベーハー・ウント・コ・カーゲー	Ｃｄ３９の発現を阻害する免疫抑制復帰オリゴヌクレオチド
US10172933B2 (en)	2016-10-31	2019-01-08	The United States Of America, As Represented By The Secretary Of Agriculture	Mosaic vaccines for serotype a foot-and-mouth disease virus
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
GB201620968D0 (en)	2016-12-09	2017-01-25	Glaxosmithkline Biologicals Sa	Adenovirus polynucleotides and polypeptides
EP3554538A2 (en)	2016-12-16	2019-10-23	Institute for Research in Biomedicine	Novel recombinant prefusion rsv f proteins and uses thereof
HUE059252T2 (hu)	2017-01-20	2022-11-28	Pfizer	Immunogén készítmények pneumokokkusz vakcinákban történõ alkalmazásra
WO2018160865A1 (en)	2017-03-01	2018-09-07	Charles Jeffrey Brinker	Active targeting of cells by monosized protocells
WO2018162450A1 (en)	2017-03-06	2018-09-13	Fundación Para La Investigación Médica Aplicada	New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2018178265A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
WO2018178264A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
JP7278259B2 (ja)	2017-04-19	2023-05-19	インスティテュート・フォー・リサーチ・イン・バイオメディシン	ワクチン及び標的としてのプラスモジウムスポロゾイトｎｐｄｐペプチド、新規マラリアワクチン、及びそれに結合する抗体
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
US20200115324A1 (en)	2017-06-11	2020-04-16	Molecular Express, Inc.	Methods and compositions for substance use disorder vaccine formulations and uses thereof
BR112019026615B1 (pt)	2017-06-15	2022-08-02	Infectious Disease Research Institute	Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
EP3655031A1 (en)	2017-07-21	2020-05-27	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Neisseria meningitidis immunogenic compositions
CN110996994A (zh)	2017-08-14	2020-04-10	葛兰素史密丝克莱恩生物有限公司	加强免疫应答的方法
US11123415B2 (en)	2017-08-16	2021-09-21	Ohio State Innovation Foundation	Nanoparticle compositions for Salmonella vaccines
CN111432836A (zh)	2017-09-05	2020-07-17	转矩医疗股份有限公司	治疗性蛋白质组合物及其制备和使用方法
US12005112B2 (en)	2017-09-07	2024-06-11	University Of Oslo	Vaccine molecules
EP3678698A1 (en)	2017-09-07	2020-07-15	University Of Oslo	Vaccine molecules
US11162099B2 (en)	2017-09-08	2021-11-02	Mina Therapeutics Limited	HNF4A saRNA compositions and methods of use
KR102755593B1 (ko)	2017-09-08	2025-01-20	액세스 투 어드밴스드 헬스 인스티튜트	사포닌을 포함하는 리포솜 제형 및 사용 방법
CA3081436A1 (en)	2017-10-31	2019-05-09	Western Oncolytics Ltd.	Platform oncolytic vector for systemic delivery
WO2019090238A1 (en)	2017-11-03	2019-05-09	Takeda Vaccines, Inc.	Zika vaccines and immunogenic compositions, and methods of using the same
EP3703745B1 (en)	2017-11-04	2024-04-10	Nevada Research & Innovation Corporation	Immunogenic conjugates and methods of use thereof
BR112020011815A2 (pt)	2017-12-15	2020-11-17	Bayer Animal Health Gmbh	oligonucleotídeos imunoestimulatórios
US11116830B2 (en)	2017-12-18	2021-09-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacterial polysaccharide-conjugated carrier proteins and use thereof
CN111741767A (zh)	2017-12-19	2020-10-02	麻省理工学院	抗原-佐剂偶联剂和使用方法
GB201721582D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	S aureus antigens and immunogenic compositions
GB201721576D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	Hla antigens and glycoconjugates thereof
WO2019143955A1 (en)	2018-01-22	2019-07-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly protective inactivated influenza virus vaccine
US20210046177A1 (en)	2018-01-26	2021-02-18	Nantcell, Inc.	Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
WO2019158636A1 (en)	2018-02-16	2019-08-22	2A Pharma Ab	Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (en)	2018-02-16	2019-08-21	2A Pharma AB	Mutated parvovirus structural protein
JP2021516045A (ja)	2018-02-28	2021-07-01	ファイザー・インク	Ｉｌ−１５バリアントおよびその使用
WO2019173438A1 (en)	2018-03-06	2019-09-12	Stc. Unm	Compositions and methods for reducing serum triglycerides
EP3774884B1 (en)	2018-03-28	2023-12-06	Sanofi Pasteur Inc.	Methods of generating broadly protective vaccine compositions comprising hemagglutinin
WO2019195284A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic influenza-ferritin polypeptides
JP2021519596A (ja)	2018-04-03	2021-08-12	サノフイＳａｎｏｆｉ	フェリチンタンパク質
JP7614842B2 (ja)	2018-04-03	2025-01-16	サノフイ	抗原性エプスタインバーウイルスポリペプチド
EP3773697A1 (en)	2018-04-03	2021-02-17	Sanofi	Antigenic ospa polypeptides
CA3095175A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic respiratory syncytial virus polypeptides
JP7511478B2 (ja)	2018-04-09	2024-07-05	チェックメイトファーマシューティカルズ	ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
WO2019204462A2 (en)	2018-04-17	2019-10-24	Celldex Therapeutics, Inc.	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
TWI803637B (zh)	2018-05-23	2023-06-01	美商輝瑞大藥廠	特異性針對gucy2c之抗體及其用途
PL3797121T3 (pl)	2018-05-23	2024-09-23	Pfizer Inc.	Przeciwciała swoiste dla CD3 i ich zastosowania
JP2021526831A (ja)	2018-06-12	2021-10-11	グラクソスミスクラインバイオロジカルズソシエテアノニム	アデノウイルスポリヌクレオチド及びポリペプチド
US12161712B2 (en)	2018-07-13	2024-12-10	University Of Georgia Research Foundation	Broadly reactive immunogens of influenza H3 virus, compositions and methods of use thereof
EP3824019A1 (en)	2018-07-19	2021-05-26	GlaxoSmithKline Biologicals SA	Processes for preparing dried polysaccharides
MX2021001479A (es)	2018-08-07	2021-04-28	Glaxosmithkline Biologicals Sa	Novedosos procesos y vacunas.
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
EP3851120A4 (en)	2018-09-11	2022-04-27	Shanghai Public Health Clinical Center	Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020068798A1 (en)	2018-09-24	2020-04-02	Guo Jimin	Living mammalian cells modified with functional modular nanoparticles
PL3891170T3 (pl)	2018-12-04	2024-12-02	The Rockefeller University	Immunogeny szczepionki przeciw hiv
EP3890775A1 (en)	2018-12-06	2021-10-13	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
JP7551618B2 (ja)	2018-12-12	2024-09-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
EP3894547A1 (en)	2018-12-12	2021-10-20	The United States of America, as represented by The Secretary, Department of Health and Human Services	Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
WO2020121159A1 (en)	2018-12-12	2020-06-18	Pfizer Inc.	Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020123989A1 (en)	2018-12-14	2020-06-18	University Of Georgia Research Foundation, Inc.	Crimean-congo hemorrhagic fever virus replicon particles and use thereof
US20220184158A1 (en)	2018-12-21	2022-06-16	Glaxosmithkline Biologicals Sa	Methods of inducing an immune response
US20220370606A1 (en)	2018-12-21	2022-11-24	Pfizer Inc.	Combination Treatments Of Cancer Comprising A TLR Agonist
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
WO2020176716A1 (en)	2019-02-28	2020-09-03	Brinker C Jeffrey	Modular metal–organic polyhedra superassembly compositions
EP3946446A1 (en)	2019-04-02	2022-02-09	Sanofi	Antigenic multimeric respiratory syncytial virus polypeptides
WO2020208502A1 (en)	2019-04-10	2020-10-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en)	2019-04-18	2020-10-22	Glaxosmithkline Biologicals Sa	Antigen binding proteins and assays
BR112021021637A2 (pt)	2019-05-20	2021-12-21	Valneva Se	Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
AU2020283768A1 (en)	2019-05-25	2021-12-23	Access To Advanced Health Institute	Composition and method for spray drying an adjuvant vaccine emulsion
EP3980056A4 (en)	2019-05-31	2023-03-29	Universidad De Chile	IMMUNOGENIC FORMULATION THAT INDUCES PROTECTION AGAINST ESCHERICHIA COLI PRODUCING SHIGA TOXIN (STEC)
EP3770269A1 (en)	2019-07-23	2021-01-27	GlaxoSmithKline Biologicals S.A.	Quantification of bioconjugate glycosylation
WO2021023691A1 (en)	2019-08-05	2021-02-11	Glaxosmithkline Biologicals Sa	Immunogenic composition
EP4021894A1 (en)	2019-08-30	2022-07-06	University of Rochester	Septin inhibitors for treatment of cancers
US20230020894A1 (en)	2019-09-18	2023-01-19	Children's Medical Center Corporation	An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
EP3799884A1 (en)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
WO2021084429A1 (en)	2019-11-01	2021-05-06	Pfizer Inc.	Escherichia coli compositions and methods thereof
US20220396797A1 (en)	2019-11-15	2022-12-15	Infectious Disease Research Institute	Rig-i agonist and adjuvant formulation for tumor treatment
JP2023503086A (ja)	2019-11-22	2023-01-26	グラクソスミスクラインバイオロジカルズソシエテアノニム	細菌サッカリド複合糖質ワクチンの用法及び用量
CN115397853A (zh)	2019-12-17	2022-11-25	辉瑞大药厂	对cd47、pd-l1具特异性的抗体及其用途
WO2021127271A1 (en)	2019-12-17	2021-06-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Live attenuated leishmania parasite vaccines with enhanced safety characteristics
WO2021165928A2 (en)	2020-02-23	2021-08-26	Pfizer Inc.	Escherichia coli compositions and methods thereof
EP4110382A1 (en)	2020-02-28	2023-01-04	Sanofi Pasteur Inc.	High dose influenza vaccine for pediatric subjects
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
EP4182346A1 (en)	2020-07-17	2023-05-24	Pfizer Inc.	Therapeutic antibodies and their uses
JP7407081B2 (ja)	2020-07-20	2023-12-28	三菱重工機械システム株式会社	印刷機および印刷機の後片付け方法
AU2021337493A1 (en)	2020-09-04	2023-05-18	Access To Advanced Health Institute	Co-lyophilized rna and nanostructured lipid carrier
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
WO2022066965A2 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting sox2 antigens
WO2022074061A1 (en)	2020-10-07	2022-04-14	Valneva Sweden Ab	Cholera vaccine formulation
WO2022083760A1 (zh)	2020-10-23	2022-04-28	江苏省疾病预防控制中心(江苏省公共卫生研究院)	融合蛋白及其应用
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
JP2023546615A (ja)	2020-10-27	2023-11-06	ファイザー・インク	大腸菌組成物およびその方法
MX2023005221A (es)	2020-11-04	2023-05-16	Pfizer	Composiciones inmunogenicas para uso en vacunas neumococicas.
JP2023549736A (ja)	2020-11-10	2023-11-29	ファイザー・インク	コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20240050561A1 (en)	2020-12-23	2024-02-15	Access To Advanced Health Institute	Solanesol vaccine adjuvants and methods of preparing same
US20220202923A1 (en)	2020-12-23	2022-06-30	Pfizer Inc.	E. coli fimh mutants and uses thereof
WO2022147373A1 (en)	2020-12-31	2022-07-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2022175423A1 (en)	2021-02-22	2022-08-25	Glaxosmithkline Biologicals Sa	Immunogenic composition, use and methods
US20240156935A1 (en)	2021-03-31	2024-05-16	Vib Vzw	Vaccine Compositions for Trypanosomatids
CA3210412A1 (en)	2021-04-09	2022-10-13	Urban Lundberg	Human metapneumo virus vaccine
KR20240006541A (ko)	2021-04-09	2024-01-15	셀덱스 쎄라퓨틱스, 인크.	Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
TW202305125A (zh)	2021-04-30	2023-02-01	美商凱立凡爾免疫治療股份有限公司	用於經修飾mhc表現之溶瘤病毒
AU2022281543A1 (en)	2021-05-28	2023-11-23	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346893A2 (en)	2021-05-28	2024-04-10	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2022311955A1 (en)	2021-07-16	2024-01-18	The Board Of Trustees Of The University Of Illinois	Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
EP4384534A1 (en)	2021-08-11	2024-06-19	Sanofi Pasteur, Inc.	Truncated influenza neuraminidase and methods of using the same
MX2024004252A (es)	2021-10-08	2024-06-28	Sanofi Pasteur Inc	Vacunas antigripales multivalentes.
WO2023079113A1 (en)	2021-11-05	2023-05-11	Sanofi	Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
EP4426343A1 (en)	2021-11-05	2024-09-11	Sanofi	Respiratory syncytial virus rna vaccine
MX2024005483A (es)	2021-11-05	2024-05-22	Sanofi Pasteur Inc	Vacunas contra influenza multivalentes que comprenden hemaglutinina recombinante y neuraminidasa y metodos para usar las mismas.
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
AU2022399574A1 (en)	2021-11-30	2024-07-11	Sanofi Pasteur Inc.	Human metapneumovirus viral vector-based vaccines
CN118338911A (zh)	2021-11-30	2024-07-12	圣诺菲·帕斯图尔公司	人偏肺病毒疫苗
US20250082745A1 (en)	2021-12-13	2025-03-13	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Bacteriophage lambda-vaccine system
WO2023111262A1 (en)	2021-12-17	2023-06-22	Sanofi	Lyme disease rna vaccine
CN118510548A (zh)	2022-01-13	2024-08-16	辉瑞公司	包含缀合的荚膜糖抗原的免疫原性组合物及其用途
JP2025503207A (ja)	2022-01-27	2025-01-30	サノフィ・パスツール	修飾されたＶｅｒｏ細胞、及びウイルス産生にこれを使用する方法
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
EP4494146A1 (en)	2022-03-14	2025-01-22	Sanofi Pasteur, Inc.	Machine-learning techniques in protein design for vaccine generation
KR20250008765A (ko)	2022-05-06	2025-01-15	사노피	핵산 백신에 대한 신호 서열
KR20250008122A (ko)	2022-05-11	2025-01-14	화이자 인코포레이티드	보존제를 갖는 백신 제형의 제조 방법
WO2023232901A1 (en)	2022-06-01	2023-12-07	Valneva Austria Gmbh	Clostridium difficile vaccine
WO2024003239A1 (en)	2022-06-29	2024-01-04	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024052882A1 (en)	2022-09-09	2024-03-14	Access To Advanced Health Institute	Immunogenic vaccine composition incorporating a saponin
TW202434283A (zh)	2022-11-04	2024-09-01	法商賽諾菲公司	呼吸道融合病毒rna疫苗接種
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en)	2022-11-22	2024-06-06	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en)	2022-12-01	2024-06-06	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
WO2024127215A2 (en)	2022-12-13	2024-06-20	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
TW202438514A (zh)	2022-12-20	2024-10-01	法商賽諾菲公司	鼻病毒mrna疫苗
WO2024149832A1 (en)	2023-01-12	2024-07-18	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024163327A1 (en)	2023-01-30	2024-08-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
WO2024166008A1 (en)	2023-02-10	2024-08-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024180262A1 (en)	2023-03-02	2024-09-06	Sanofi	Compositions for use in treatment of chlamydia
WO2024186635A2 (en)	2023-03-03	2024-09-12	Celldex Therapeutics, Inc.	Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024201324A2 (en)	2023-03-30	2024-10-03	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en)	2023-04-14	2024-10-17	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20240374698A1 (en)	2023-05-05	2024-11-14	Sanofi	Compositions for use in treatment of acne
US20250009865A1 (en)	2023-05-10	2025-01-09	Sanofi	Combination respiratory mrna vaccines
US20240398932A1 (en)	2023-05-11	2024-12-05	Sanofi Pasteur Inc.	Respiratory syncytial virus vaccine and methods of use
WO2024241172A2 (en)	2023-05-19	2024-11-28	Glaxosmithkline Biologicals Sa	Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2024246358A1 (en)	2023-06-01	2024-12-05	Sanofi	Thermostable compositions comprising mrna lipid nanoparticles
WO2025006737A1 (en)	2023-06-30	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025017202A2 (en)	2023-07-19	2025-01-23	Sanofi	Porphyromonas gingivalis antigenic constructs
US20250090650A1 (en)	2023-09-06	2025-03-20	Sanofi	Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2034118A1 (en) †	1970-07-09	1972-01-13	Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München	Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4956296A (en) *	1987-06-19	1990-09-11	Genex Corporation	Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5059519A (en) *	1986-07-01	1991-10-22	University Of Massachusetts Medical School	Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
CA1339596C (en)	1987-08-07	1997-12-23	New England Medical Center Hospitals, Inc.	Viral expression inhibitors
US5786189A (en) *	1989-11-29	1998-07-28	Smithkline Beecham Biologicals (S.A.)	Vaccine
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
EP0468520A3 (en) †	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
ES2104717T3 (es)	1990-08-16	1997-10-16	Isis Pharmaceuticals Inc	Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus.
US5234811A (en) *	1991-09-27	1993-08-10	The Scripps Research Institute	Assay for a new gaucher disease mutation
CA2122132A1 (en) *	1991-11-18	1993-05-27	Tse Wen Chang	Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production
US5585479A (en) *	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
WO1994002471A1 (en)	1992-07-24	1994-02-03	Kumiai Chemical Industry Co., Ltd.	Triazole derivative, process for producing the same, pest control agent, and pest control method
JPH08502723A (ja) †	1992-07-27	1996-03-26	ハイブライドンインコーポレイテッド	オリゴヌクレオチド・アルキルホスホノチオエート
US5840497A (en) *	1993-06-11	1998-11-24	The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization	Method for specific silencing of genes by DNA methylation
WO1995026204A1 (en) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
PT772619E (pt) *	1994-07-15	2006-10-31	Univ Iowa Res Found	Oligonucleotidos imunomoduladores
US5629052A (en)	1995-02-15	1997-05-13	The Procter & Gamble Company	Method of applying a curable resin to a substrate for use in papermaking

1995
- 1995-02-07 PT PT95911630T patent/PT772619E/pt unknown
- 1995-02-07 DK DK95911630.2T patent/DK0772619T4/da active
- 1995-02-07 US US08/386,063 patent/US6194388B1/en not_active Expired - Lifetime
- 1995-02-07 AT AT01202813T patent/ATE509102T1/de not_active IP Right Cessation
- 1995-02-07 AT AT01202811T patent/ATE420171T1/de not_active IP Right Cessation
- 1995-02-07 DE DE69535905T patent/DE69535905D1/de not_active Expired - Lifetime
- 1995-02-07 EP EP95911630A patent/EP0772619B2/en not_active Expired - Lifetime
- 1995-02-07 ES ES95911630T patent/ES2267100T5/es not_active Expired - Lifetime
- 1995-02-07 DE DE69535036T patent/DE69535036T3/de not_active Expired - Lifetime
- 1995-02-07 WO PCT/US1995/001570 patent/WO1996002555A1/en active IP Right Grant
- 1995-02-07 ES ES01202811T patent/ES2320315T5/es not_active Expired - Lifetime
- 1995-02-07 EP EP01202814A patent/EP1167379A3/en not_active Ceased
- 1995-02-07 AT AT95911630T patent/ATE328890T1/de active
- 1995-02-07 ES ES01202813T patent/ES2366201T3/es not_active Expired - Lifetime
- 1995-02-07 CA CA002194761A patent/CA2194761C/en not_active Expired - Lifetime
- 1995-02-07 EP EP01202813A patent/EP1167378B1/en not_active Expired - Lifetime
- 1995-02-07 AU AU19127/95A patent/AU713040B2/en not_active Expired
- 1995-02-07 EP EP01202811A patent/EP1167377B2/en not_active Expired - Lifetime
- 1995-02-07 JP JP50499196A patent/JP3468773B2/ja not_active Expired - Lifetime
- 1995-02-07 CA CA002560114A patent/CA2560114A1/en not_active Abandoned
2002
- 2002-05-13 HK HK02103584.4A patent/HK1043598A1/zh unknown
- 2002-06-26 HK HK02104747.6A patent/HK1044950A1/zh not_active IP Right Cessation
- 2002-06-26 HK HK02104746.7A patent/HK1044949B/zh not_active IP Right Cessation
- 2002-10-16 JP JP2002302338A patent/JP2003144184A/ja not_active Withdrawn
2003
- 2003-06-23 JP JP2003178741A patent/JP4126252B2/ja not_active Expired - Lifetime
- 2003-06-23 JP JP2003178740A patent/JP2004024261A/ja not_active Withdrawn
2004
- 2004-03-11 JP JP2004069838A patent/JP2004215670A/ja not_active Withdrawn
2008
- 2008-01-25 JP JP2008015654A patent/JP2008169216A/ja not_active Withdrawn
2009
- 2009-03-10 JP JP2009057160A patent/JP2009148296A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69535905D1 (de)	2009-02-26
DE69535036D1 (de)	2006-07-20
EP1167378A3 (en)	2005-08-17
ES2320315T5 (es)	2012-12-05
EP0772619B1 (en)	2006-06-07
ATE328890T1 (de)	2006-06-15
HK1044949B (zh)	2012-01-27
CA2194761C (en)	2006-12-19
AU1912795A (en)	1996-02-16
EP1167378B1 (en)	2011-05-11
JP2003144184A (ja)	2003-05-20
EP1167377B2 (en)	2012-08-08
EP0772619A1 (en)	1997-05-14
EP1167377A3 (en)	2004-09-08
EP1167379A2 (en)	2002-01-02
DK0772619T3 (da)	2006-10-09
HK1044950A1 (zh)	2002-11-08
ES2320315T3 (es)	2009-05-21
HK1044949A1 (en)	2002-11-08
JP2009148296A (ja)	2009-07-09
WO1996002555A1 (en)	1996-02-01
AU713040B2 (en)	1999-11-18
CA2560114A1 (en)	1996-02-01
EP1167379A3 (en)	2004-09-08
DE69535036T3 (de)	2011-07-07
JPH10506265A (ja)	1998-06-23
JP2008169216A (ja)	2008-07-24
EP1167378A2 (en)	2002-01-02
DE69535036T2 (de)	2007-01-18
ATE420171T1 (de)	2009-01-15
DK0772619T4 (da)	2011-02-21
EP1167377B1 (en)	2009-01-07
JP2004215670A (ja)	2004-08-05
ATE509102T1 (de)	2011-05-15
EP0772619B2 (en)	2010-12-08
JP3468773B2 (ja)	2003-11-17
US6194388B1 (en)	2001-02-27
EP1167377A2 (en)	2002-01-02
JP4126252B2 (ja)	2008-07-30
ES2366201T3 (es)	2011-10-18
HK1043598A1 (zh)	2002-09-20
JP2004043466A (ja)	2004-02-12
CA2194761A1 (en)	1996-02-01
ES2267100T3 (es)	2007-03-01
ES2267100T5 (es)	2011-04-08
JP2004024261A (ja)	2004-01-29

Publication	Publication Date	Title
DE69535036D1 (de)	2006-07-20	Immunomodulatorische oligonukleotide
ZA9811849B (en)	2000-06-23	Vaccine.
ZA988789B (en)	2000-03-29	Vaccine.
DE69727183D1 (de)	2004-02-19	Angetriebenes Handstück
EP0674876A3 (en)	1995-12-27	Surgical stapling instrument.
EP0677273A3 (en)	1995-12-13	Surgical stapler.
DE69816696D1 (de)	2003-09-04	Pneumatisches chirurgisches Handstück
IS4812A (is)	1998-07-28	Samsett meðferð fyrir beingisnun
IT1292837B1 (it)	1999-02-11	Apparecchio chirurgico per biopsia.
DZ2283A1 (fr)	2002-12-25	Composition de vaccin.
ZA973642B (en)	1997-11-25	DNA vaccine formulations.
IT1302338B1 (it)	2000-09-05	Dispositivo per l'azionamento del freno di un veicolo.
ZA971250B (en)	1997-08-27	Dental syringe.
HU9603567D0 (en)	1997-02-28	Combination therapy for hiv infection
ZA9810445B (en)	1999-07-01	Novel bone surgical device.
ZA984696B (en)	1999-01-04	Vaccine compositions V.
ES1027473Y (es)	1995-02-16	Boton quirurgico de traccion ortodoncia.
ITBO940414A0 (it)	1994-09-21	Manipolo endoorale per riprese di video-immagini.
ITBO930113V0 (it)	1993-05-19	supporto per strumenti odontoiatrici accessori.
ES1028663Y (es)	1995-07-01	Depresor lingual.
ITBO970084A0 (it)	1997-02-21	Manipolo dentale per la rimozione del tartaro.
ES1030157Y (es)	1996-01-16	Depresor lingual.
BR9401338A (pt)	1995-10-24	Bocal para lâmpadas de encaixe por pressão das mesmas
ITBO970569A0 (it)	1997-09-22	Fascetta multiuso per chirurgia ortopedica.
ES1025872Y (es)	1994-09-01	Maquina de traccion cervical.